BCM
AZN icon

Bienville Capital Management’s AstraZeneca AZN Stock Holding History

Bienville Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,178
Closed -$230K – 129
2020
Q2 		$230K Buy
+2,178
New +$225K 0.02% 122
2015
Q1 		– Sell
-9,000
Closed -$633K – 56
2014
Q4 		$633K Buy
+9,000
New +$644K 0.52% 32

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bienville Capital Management's AZN Position: Q3 2020 in Review

Bienville Capital Management sold out of AstraZeneca (AZN) in Q3 2020, closing a stake of 2,178 shares — an estimated $230K sold.

Bienville Capital Management first reported a position in AZN in Q4 2014 and held it in 2 quarters. The position peaked at $633K in Q4 2014. 723 funds tracked by Wall St. Rank hold AZN as of Q3 2020.

  • Bienville Capital Management reported no remaining AstraZeneca position as of Q3 2020 after selling out during the quarter.
  • Bienville Capital Management sold 2,178 AstraZeneca shares in Q3 2020, an estimated $230K.
  • Bienville Capital Management first reported a position in AstraZeneca in Q4 2014 and held it in 2 quarters.
  • Bienville Capital Management's AstraZeneca position peaked at $633K in Q4 2014.
  • 723 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2020.

Based on Bienville Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.